GlassScriptPhysician profile
Corey W Cleland
NPI 1760938047
$8,643.93
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,288 · 2022: $2,068 · 2023: $2,332 · 2024: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,192.10 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,321.05 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $840.47 | 2021-2024 | |
| Glaxosmithkline, LLC. | $653.18 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $603.67 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $548.48 | 2022-2024 | |
| Amarin Pharma, INC. | $540.00 | 2021-2023 | |
| Mannkind Corporation | $387.98 | 2023-2024 | Afrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $362.22 | 2022-2024 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $342.87 | 2021 | |
| Dexcom, INC. | $306.97 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $288.70 | 2023-2024 | Korlym |
| Lilly USA, LLC | $280.74 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Cequr Corporation | $244.83 | 2024 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.55 | 2021-2024 | Jardiance |
| Zealand Pharma US, INC. | $191.10 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Cleland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.